2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, Illinois, US 02 June 2023 - 06 June 2023
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
06 Jul 2023
Sacituzumab govitecan proven safe, effective in metastatic breast cancer
Treatment with sacituzumab govitecan (SG) demonstrates clinically meaningful overall survival (OS) over single-agent chemotherapy in patients with pretreated, endocrine-resistant, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), as confirmed by the final OS analysis from the TROPiCS-02 study, presented at ASCO 2023.
Sacituzumab govitecan proven safe, effective in metastatic breast cancer
26 Jun 2023
Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma
Treatment with nivolumab (N) plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to improved progression-free survival (PFS) relative to brentuximab vedotin (BV) plus AVD in patients with advanced stage classic Hodgkin lymphoma (HL), according to the results of the SWOG S1826 study, which was presented at the recent ASCO 2023.
Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma
22 Jun 2023
Erdafitinib prevails in bladder cancer with select FGFRalt
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.
Erdafitinib prevails in bladder cancer with select FGFRalt
22 Jun 2023
Ribociclib plus endocrine therapy: A win for early breast cancer?
In the second interim efficacy analysis of the phase III NATALEE trial, a combination regimen comprising the CDK4/6 inhibitor ribociclib and endocrine therapy (ET) demonstrated favourable signals for the adjuvant treatment of stage II/III hormone receptor-positive, HER2-negative (HR+, HER2–) early breast cancer.
Ribociclib plus endocrine therapy: A win for early breast cancer?
16 Jun 2023
Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK
For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.